Sana Biotechnology

Sana Biotechnology and SAB Biotherapeutics are small-cap medical companies. Analysts favor SAB Biotherapeutics due to higher potential upside. Sana Biotechnology has stronger institutional ownership and insider ownership. SAB Biotherapeutics has higher revenue and earnings. Sana Biotechnology is less volatile, while SAB Biotherapeutics has higher profitability metrics. Sana Biotechnology outperforms on 6 of 10 factors.

Sana Biotechnology has a cash runway of 11 months, with a cash burn of $285m and $252m in cash reserves. The company's cash burn reduction by 2.3% suggests cautious management, but its cash burn relative to market cap raises concerns. Dilution risk is significant if additional funding is needed.

Invest in AI now for exponential growth, disruption, and a talent-rich future. A specific AI stock offers potential for 10,000% returns. Subscribe to a newsletter for exclusive insights on this opportunity.

Sana Biotechnology appoints Dhaval Patel, M.D., Ph.D., as Executive VP and Chief Scientific Officer to lead research, drug discovery, and development.

Jeff Bezos' investments include Sana Biotechnology, Inc. (NASDAQ:SANA), which focuses on treating complex diseases. SANA ranks 8th among Bezos' stocks, with Citi raising its price target to $15.00 and Baker Bros. Advisors as its largest shareholder. Despite SANA's potential, other AI stocks may offer higher returns.

AI is the greatest investment opportunity of our lifetime, poised for exponential growth and disruption across industries. Early investors stand to gain significantly, with potential returns of up to 10,000%. A specific AI stock is highlighted as a 'diamond in the rough,' offering massive potential. Exclusive access to detailed investment research and insights is available through a discounted Premium Readership Newsletter subscription.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account usually reactivates within 24 hours; contact support if still disabled.

Marshall Wace LLP reduced its Sana Biotechnology, Inc. position by 78.4% in Q2, owning 187,713 shares worth $1,025,000. Other hedge funds also adjusted their positions, with Vanguard Group Inc. increasing its stake by 24.1% and owning 12,155,173 shares valued at $121,552,000. Insiders own 31.10% of the company's stock, and institutional investors hold 88.23%.

Sana Biotechnology's stock dropped 4.2% to $4.06, with 81,766 shares traded, down 96% from the average volume. Analysts from Citigroup, HC Wainwright, and Rodman & Renshaw maintain 'buy' ratings with updated price targets. The company reported a -$0.32 EPS, missing estimates by -$0.04. Director Richard Mulligan sold 150,000 shares at $4.08 each. Institutional investors increased their holdings, with 88.23% ownership.

Sana Biotechnology, with no Q2 2024 revenues but $251.6M in cash, reported better-than-expected EPS of ($0.21). Key R&D focuses include SC291/SC262 for hematological malignancies, modified pancreatic islet cell IST, and SC291 for autoimmune diseases. Data updates crucial for valuation, with potential stock upside of 411% and downside risk of 80%. Strong cash position offers flexibility and reduces near-term dilution risk.